A Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund Its Cancer Programs
The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.
Photo: Vitaly Gariev / Pexels
Reported by Inc..
Read the full story at Inc.
